Compare CWT & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWT | SUPN |
|---|---|---|
| Founded | 1926 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | N/A | 2012 |
| Metric | CWT | SUPN |
|---|---|---|
| Price | $44.60 | $44.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $54.50 | ★ $63.25 |
| AVG Volume (30 Days) | 369.2K | ★ 1.0M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $1,002,357,000.00 | $681,539,000.00 |
| Revenue This Year | N/A | $8.29 |
| Revenue Next Year | $7.38 | $22.72 |
| P/E Ratio | $19.53 | ★ N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $41.64 | $29.16 |
| 52 Week High | $51.63 | $57.65 |
| Indicator | CWT | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 38.66 |
| Support Level | $43.94 | $44.37 |
| Resistance Level | $46.32 | $47.00 |
| Average True Range (ATR) | 0.92 | 1.39 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 28.91 | 10.85 |
California Water Service Group is a U.S. water and utilities holding company based in California. The company engages in the production, treatment, storage, distribution, and sale of water for various uses. The firm operates through its subsidiaries, which can be divided between regulated and unregulated businesses. The regulated public utilities subsidiaries operate in California, New Mexico, Washington, and Hawaii. The unregulated subsidiaries provide water utility services to private companies and municipalities. The company derives the majority of its revenue from its operations in California and, overall, from residential customers.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.